Telix has announced the launch of the international NOBLE Registry of its ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient.
AusBiotech
New Stories
-
Telix launches international NOBLE Registry of SPECT-Based prostate cancer imaging agent
April 20, 2021 - - Latest News -
Australian medtech consultancy merges with international leader
April 20, 2021 - -
Exopharm completes $12 million capital raise
April 20, 2021 - - Latest News -
Race Oncology appoints chief medical officer
April 20, 2021 - - Latest News -
AusBiotech appoints new director - Dr James Campbell
April 20, 2021 - - AusBiotech -
Pharmaxis sells Bronchitol rights in Russia and completes placement
April 15, 2021 - - Latest News -
Ex-AusBiotech CEO joins board of emerging local biotech
April 15, 2021 - - Latest News